role of rebates in glp-1 pbm decisions CMS Issues Coverage Guidance on Anti-Obesity Drugs February 9, 2026: PBMs are

These analyses compared GLP-1 receptor agonists with other glucose-lowering medications such as DPP-4 inhibitors and insulin

But, they work by bypassing the bodys natural systems and in some cases lowering the bodys ability to naturally perform these actions as the body gets used to receiving them

Obesity is a chronic condition associated with diabetes, heart disease, stroke and other health risks

3 Participants on oral semaglutide lost an average of about 16.6% of their body weight

Something else that didn't feature heavily (if at all) in the earnings calls themselves, but that undoubtedly contributed to insurers' performance improvement: denials

Approved by the U.S